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j.jtcvs.2012.12.086Reply to the Editor:
We appreciate the thoughtful com-
ments that Cantinotti and colleagues
expressed in their letter. Cantinotti
and colleagues are to be commended
for their important body ofwork,which
has advanced the understanding of
B-type natriuretic peptide (BNP) levels
in pediatric patients with congenital
heart disease.1
We agree that levels of BNP are age
dependent both in healthy neonates and
in those with congenital heart disease.
Also, as we indicated in the recent
article under discussion,2 the rapid
changes in BNP levels after surgical in-
tervention (within hours of the opera-
tion) imply that there are physiologic
changes associated with the specific
surgical interventions because of the
particular underlying cardiac defects
that determine the release of BNP.
Indeed, neonates with univentricular
physiology havevery highpreoperative
BNP levels relative to those of age-
matched healthy neonates and also rel-
ative to those with left-to-right shunts.
In our study, there was also a trend to-
ward higher BNP levels in neonates
with univentricular physiology relative
to those undergoing an arterial switch
operation.We believe this is one reason
that studies grouping neonates into sin-
gle cohorts,3,4 without consideration1416 The Journal of Thoracic andfor the specific cardiac defects, have
not found the postoperative decreases
in BNP that both we2 and Cantinotti
and colleagues1 found.
We therefore caution against relying
on disease severity scoring systems that
group diverse cardiac defects within
particular categories or combine vari-
ous diagnostic criteria, such as the
Risk Adjustment for Congenital Heart
Surgery 1 and Aristotle Basic Com-
plexity scores, for the interpretation of
perioperative BNP levels. Indeed, these
scoring systemsdonot fully account for
the variability in outcomes seen, dem-
onstrating that other factors remain
important.5 In attempting to understand
better the physiologic release of a bio-
marker and its implications for prog-
nostication and goal-directed therapy,
the use of such scoring systems is there-
fore likely to fall short in accounting for
the variability in levels of the bio-
marker. In fact, in Figure 1 of the letter
of Cantinotti and colleagues, neonates
in Aristotle Basic Complexity cate-
gories II and III can be seen to have
more variability in BNP levels than
those in category IV, probably because
of the differences in cardiac lesions and
the physiologic changes associated
with surgery that inherently differ by
category in these systems.A further ex-
ample of the specificitywe described in
our study was shown in preliminary
data from our previous work, where
we found that preoperative BNP level
in patients undergoing a total cavopul-
monary connection (Fontan procedure)
was the only significant predictor of
adverse postoperative outcomes.6
There is clearly much to learn about
the mechanisms involved in BNP re-
lease in patients with congenital heart
disease and the utility of this biomarker
in this population. We agree with Can-
tinotti and colleagues that further inves-
tigations into BNP changes during the
perioperative period are warranted.
On the basis of our combined data to
date, we believe that fully understand-
ing and interpreting perioperative
BNP changes will require accounting
for age, the cardiac lesion, and theCardiovascular Surgery c May 2013intervention that is undertaken. We
thank both the Editor and Cantinotti
and colleagues for this opportunity to
highlight this important topic.
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To the Editor:
We read with great interest the arti-
cle entitled, ‘‘Tracheal regeneration:
Evidence of bone marrow mesenchy-
mal stem cell involvement,’’ by
Seguin and coworkers.1 We congratu-
late Seguin and coworkers1 for their
convincingdemonstration ofbonemar-
row–derived stem cell migration to the
grafted area after tracheal replacement
FIGURE1. A, Pathologic examination of a fascial flap–wrapped fresh allogeneic aorta after insertion
of a too-wide polyethylene tube, showing a necrotic aortic graft circumference (arrowhead) charac-
terized by the evanescence of smooth cells into the elastic fiber network (hematoxylin eosin and saf-
fron stain, original magnification 2003). B, By comparison, fascial flap–wrapped fresh allogeneic
aorta after an adequate tube insertion, showing a viable aortic graft circumference (arrowhead; hema-
toxylin eosin and saffron stain, original 2003). Black stars indicate the surrounding fascia.
Letters to the Editorwith an aortic allograft in a New Zea-
land rabbit model. In the same model,
we previously investigated the revascu-
larization process in both fresh and cry-
opreserved thoracic aortic allografts
after fascial wrap in a heterotopic posi-
tion and then the construction of an aor-
tic graft–based tracheal substitute.2,3
Our preliminary anatomic studies
discovered a significant discrepancy
between the tracheal and thoracic
aortic inner diameters (approximately
6 mm and 4 mm wide, respectively),
and we first attempted to solve this
issue by forced insertion of a 4.8-mm
wide polyethylene tube, increasing
the aortic graft diameter and maintain-
ing a patent lumen during the revascu-
larization period. Unfortunately, this
overdistention invariably led to graft
necrosis (Figure 1), characterized byThe Journalevanescence of smooth cells into the
elastic fiber network of the aortic wall
and inconsistent calcification deposits
(unpublished data). Given the need
for forced insertion of a 5-mmdiameter
stent supporting the aortic allograft in
Seguin and coworkers’ study,1 we
would like to know whether such ne-
crotic lesions as described here were
observed in the aortic graft tissue of an-
imals that died or were killed at less
than 1 month. We hypothesize that
such a necrotic scaffold, containing
only residual elastic fibers, makes re-
generation of mature tracheal tissue
improbable aside from nonspecific ep-
ithelial cell ingrowths.1 The presence
of bone marrow mesenchymal stem
cells in the grafted area could result in
their capacity for nonspecificmigration
and homing toward different kinds ofof Thoracic and Cardiovascular Surgerdamaged or injured tissues.4 As stated
by Seguin and coworkers,1 only islands
of nascent cartilage were shown in
close proximity to anastomoses. The
origin of these cartilaginous islets,
however, remains elusive because of
the negative results for Y chromosome
detection. Furthermore, the relevance
of these cartilaginous islets was not ex-
plored, because animals surviving lon-
ger than a year did not have any
attempt at removing the stent to prove
a successfully regenerated or remod-
eled airway. These disappointing re-
sults contrast with confirmed tracheal
regeneration in allogeneic aortic grafts
observed after the landmark investiga-
tions of long tracheal replacements in
sheep and minipig models,5,6 which in
fact were all conducted on juvenile
animals (continuing their growth even
though sexually mature). One might
hypothesize that such a favorable out-
come could result from the high level
of secretion of growth hormone, which
directly stimulates tissue regeneration
and chondrocyte multiplication.
In fact, the mesenchymal stem cell
mobilization to the graft area and carti-
laginous islets shown here are more in
line with clinical results in the long-
term follow-up (mean, 70 months) of
our aortic allograft–grafted adult pa-
tients,7who currently still require stent-
ing and therefore show no evidence of
actual clinically relevant tracheal re-
modeling into the graft.
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j.jtcvs.2012.12.088Reply to the Editor:
We read with interest the comments
addressed by Wurtz and coworkers on
our article, ‘‘Tracheal regeneration:
Evidence of bone marrow stem cell in-
volvement.’’1 We greatly appreciate
their congratulations for having pro-
vided a ‘‘convincing demonstration of
bonemarrow–derived stem cell migra-
tion to thegrafted area after tracheal re-
placement with an aortic allograft in
a New Zealand rabbit model.’’ More
generally, we thank them for their
strong support to our pioneering exper-
imental works,2-5 which led to the first
human applications.6,7 Nevertheless,
we would like to discuss some key
points arising from their letter.
In our rabbit model, we observed
a radically different evolution of the
aortic graft. To answer precisely their
comments, neither necrosis nor over-
distention of the thoracic aorta by the
endoprosthesis occurred in our exper-
iments. A stent of 5 mm in diameter1418 The Journal of Thoracic andwas inserted with moderate distention
of the aorta so that the elastic tissue
would not collapse. As shown in Fig-
ure 1 of the original article, stent and
aortic dimensions matched well with
the cervical tracheal diameter after
graft interposition. Moreover, as
underlined by our article, stent migra-
tion was one of the main complica-
tions, proving that the stenting has
not been forcefully made. Perhaps
age and weight of the rabbits in Wurtz
and coworkers’ experimentations
were not properly chosen? We are
also surprised by the polyethylene
tube they reported using in their un-
published studies. In our sheep and hu-
man work, we paid great attention to
base our studies on a tracheal prosthe-
sis that had already been evaluated in
clinical applications, and we decided
to use a flexible pediatric tracheal sili-
cone stent (Tracheobronxane Dumon;
Novatech, La Ciotat, France).
Finally, did Wurtz and coworkers
observe such necrosis both with and
without stenting in their model? The
real difference that we want to under-
line is the allotransplantation site of
the aorta. Also, a muscle flap could
be a better option than a fascial flap
to promote revascularization. This
has been clearly demonstrated in our
experimental and clinical work on air-
way transplantation with aortic
allografts.7,8
We completely agree with Wurtz
and coworkers that ‘‘the presence of
bone marrow mesenchymal stem cells
in the grafted area could result in their
capacity for nonspecific migration and
homing toward different kinds of dam-
aged or injured tissues.’’ As they have
noted, we constructed our experimen-
tations on the basis of mesenchymal
stem cell circulating theory, hypothe-
sizing that injured rabbits would use
circulating mesenchymal stem cells
to avoid bone marrow mobilization.9
It is well known that unspecific
mesenchymal stem cells migrate to in-
flammatory sites attracted by the liber-
ation of chemokines on the place of
injury. The real challenge is to findCardiovascular Surgery c May 2013the other triggers orienting these cells
to secondly differentiate to obtain tra-
cheal regeneration.
We disagree with Wurtz and co-
workers, however, who would com-
pare these uncompleted results on
the rabbit model with the first human
applications, in which cartilage regen-
eration seems to be delayed. The
structure of the human aorta is histo-
logically closer to the aorta of the min-
ipig than to the aorta of the rabbit.
There is still hope to get similar results
to those observed in these experimen-
tations with cartilage regeneration.
We are still working on multiple hy-
potheses to explain the delayed regen-
eration of human cartilage, such as
patient age (older meaning no circu-
lating growth factor), sex influence
(more often men than women), tu-
moral pathology, previous impairing
treatments (chemotherapy), and so on.
To conclude, the myth turned into
reality with the first demonstration of
tracheal regeneration in animal studies
at the beginning of our experience.2-4
Today, the main issue is to obtain
the same regenerative processes in
human beings. A prospective study
(TRACHEOBRONC-ART trial) is in
progress at our center to confirm not
only the feasibility of airway
transplantation with cryopreserved
aortic allograft but also the
possibility of airway regeneration in
human beings.
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